Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands

► Combined RSV antigen/innate ligand adjuvants augments local IgA responses. ► Supplementation with innate ligand adjuvants skews towards Th1 responses. ► Combined RSV antigen/innate ligand adjuvants provides protection against infection. ► Combined RSV antigen/innate ligand adjuvants does not prime for enhanced disease.